JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders
This case series found that JAK2 fusions were seen in aggressive cytotoxic CTCL as well as in T-cell lymphomas with more indolent behavior, possibly representing a precursor lesion to aggressive evolution with age and comorbidities. The prominence of these fusions supports a potentially larger role for JAK2 targeting in patients with early-stage MF, CD30-positive LPD, or overlap presentations.
Authors
- Shamir Geller (ORCID: https://orcid.org/0000-0003-1206-1057)
- Leore Lavin (ORCID: https://orcid.org/0000-0002-2793-5282)
- Haiming Tang (ORCID: https://orcid.org/0000-0001-7058-349X)
- Melissa Pulitzer (ORCID: https://orcid.org/0000-0002-0606-9186)
- César A. Virgen (ORCID: https://orcid.org/0000-0001-5273-7360)
- Andrea P. Moy (ORCID: https://orcid.org/0000-0001-5431-6682)
- Lane F. Donnelly (ORCID: https://orcid.org/0000-0003-1882-3518)
- Viviane Liao (ORCID: https://orcid.org/0000-0001-9355-1298)
- Mi-Sook Do
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Weill Cornell Medicine (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JAMA Dermatology
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1001/jamadermatol.2025.4688
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Cancer Institute